Baird raised the firm’s price target on Castle Biosciences to $37 from $34 and keeps an Outperform rating on the shares. The firm said they reported 2Q revenue/profitability well ahead of expectations, largely driven by strong TissueCypher/DecisionDx-SCC outperformance. Baird said while the pending Novitas DecisionDx-SCC reimbursement decision could continue to provide an overhang near term, they’re encouraged by the update and continue to believe shares are undervalued at current levels,
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Unveils Strategy in Management Presentations
- CSTL Earnings this Week: How Will it Perform?
- Canaccord recommends buying Castle Biosciences on weakness after MolDX news
- Castle MolDX update doesn’t impact current Dx-SCC Medicare coverage, says Baird
- Castle Biosciences downside risk ‘limited’ on MolDx decision, says Leerink